BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

881 related articles for article (PubMed ID: 31714955)

  • 1. Does Addition of Intravenous Metronidazole to Oral Vancomycin Improve Outcomes in Clostridioides difficile Infection?
    Wang Y; Schluger A; Li J; Gomez-Simmonds A; Salmasian H; Freedberg DE
    Clin Infect Dis; 2020 Dec; 71(9):2414-2420. PubMed ID: 31714955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Addition of Intravenous Metronidazole to Oral Vancomycin Therapy in Critically Ill Patients with Non-Fulminant Severe Clostridioides difficile Infection.
    Vega AD; Heil EL; Blackman AL; Banoub M; Kristie Johnson J; Leekha S; Claeys KC
    Pharmacotherapy; 2020 May; 40(5):398-407. PubMed ID: 32246501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Oral Vancomycin for Clostridioides difficile Infection and the Risk of Vancomycin-Resistant Enterococci.
    Stevens VW; Khader K; Echevarria K; Nelson RE; Zhang Y; Jones M; Timbrook TT; Samore MH; Rubin MA
    Clin Infect Dis; 2020 Jul; 71(3):645-651. PubMed ID: 31504328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Significance of Toxigenic Clostridioides difficile Growth in Stool Cultures during the Era of Nonculture Methods for the Diagnosis of C. difficile Infection.
    Lee CC; Lee JC; Chiu CW; Tsai PJ; Ko WC; Hung YP
    Microbiol Spectr; 2021 Oct; 9(2):e0079921. PubMed ID: 34668727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes associated with recent guideline recommendations removing metronidazole for treatment of non-severe Clostridioides difficile infection: a retrospective, observational, nationwide cohort study.
    Gentry CA; Campbell DL; Williams RJ
    Int J Antimicrob Agents; 2021 Mar; 57(3):106282. PubMed ID: 33465458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-inferiority of metronidazole to vancomycin in the treatment of first episode non-severe Clostridioides difficile infection: a single center retrospective cohort study.
    Najjar-Debbiny R; Bazazhina A; Schwartz N; Shaked P; Saliba W; Weber G
    Infection; 2022 Aug; 50(4):973-980. PubMed ID: 35192148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Effectiveness of Vancomycin and Metronidazole for the Prevention of Recurrence and Death in Patients With Clostridium difficile Infection.
    Stevens VW; Nelson RE; Schwab-Daugherty EM; Khader K; Jones MM; Brown KA; Greene T; Croft LD; Neuhauser M; Glassman P; Goetz MB; Samore MH; Rubin MA
    JAMA Intern Med; 2017 Apr; 177(4):546-553. PubMed ID: 28166328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Clostridioides difficile Infection and Non-compliance with Treatment Guidelines in Adults in 10 US Geographical Locations, 2013-2015.
    Novosad SA; Mu Y; Winston LG; Johnston H; Basiliere E; Olson DM; Farley MM; Revis A; Wilson L; Perlmutter R; Holzbauer SM; Whitten T; Phipps EC; Dumyati GK; Beldavs ZG; Ocampo VLS; Davis CM; Kainer M; Gerding DN; Guh AY
    J Gen Intern Med; 2020 Feb; 35(2):412-419. PubMed ID: 31768906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study.
    Polivkova S; Krutova M; Capek V; Sykorova B; Benes J
    Int J Infect Dis; 2021 Feb; 103():226-233. PubMed ID: 33188906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral vancomycin versus metronidazole for the treatment of Clostridioides difficile infection: Meta-analysis of randomized controlled trials.
    Igarashi Y; Tashiro S; Enoki Y; Taguchi K; Matsumoto K; Ohge H; Suzuki H; Nakamura A; Mori N; Morinaga Y; Yamagishi Y; Yoshizawa S; Yanagihara K; Mikamo H; Kunishima H
    J Infect Chemother; 2018 Nov; 24(11):907-914. PubMed ID: 30170735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Oral Metronidazole, Vancomycin, and Fidaxomicin on Host Shedding and Environmental Contamination With Clostridioides difficile.
    Turner NA; Warren BG; Gergen-Teague MF; Addison RM; Addison B; Rutala WA; Weber DJ; Sexton DJ; Anderson DJ
    Clin Infect Dis; 2022 Mar; 74(4):648-656. PubMed ID: 34017999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization and risk factors for recurrence of Clostridioides (Clostridium) difficile infection in Japan: A nationwide real-world analysis using a large hospital-based administrative dataset.
    Kimura T; Snijder R; Sugitani T
    J Infect Chemother; 2019 Aug; 25(8):615-620. PubMed ID: 30987950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-hospitalization Treatment Regimen and Readmission for C. difficile Colitis in Medicare Beneficiaries.
    Psoinos CM; Collins CE; Ayturk MD; Anderson FA; Santry HP
    World J Surg; 2018 Jan; 42(1):246-253. PubMed ID: 28744593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibiotics for Treatment of Clostridium difficile Infection in Hospitalized Patients with Inflammatory Bowel Disease.
    Horton HA; Dezfoli S; Berel D; Hirsch J; Ippoliti A; McGovern D; Kaur M; Shih D; Dubinsky M; Targan SR; Fleshner P; Vasiliauskas EA; Grein J; Murthy R; Melmed GY
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5054-9. PubMed ID: 24913174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clostridioides difficile infection in paediatric patients with cancer and haematopoietic stem cell transplant recipients.
    Haeusler GM; Lehrnbecher T; Agyeman PKA; Loves R; Castagnola E; Groll AH; van de Wetering M; Aftandilian CC; Phillips B; Chirra KM; Schneider C; Dupuis LL; Sung L
    Eur J Cancer; 2022 Aug; 171():1-9. PubMed ID: 35696884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral Vancomycin Monotherapy Versus Combination Therapy in Solid Organ Transplant Recipients With Uncomplicated Clostridium difficile Infection: A Retrospective Cohort Study.
    Korayem GB; Eljaaly K; Matthias KR; Zangeneh TT
    Transplant Proc; 2018; 50(1):137-141. PubMed ID: 29407296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of antibiotic therapy for Clostridioides difficile infection on mortality and other patient-relevant outcomes: a systematic review and meta-analysis.
    Stabholz Y; Paul M
    Clin Microbiol Infect; 2024 Jan; 30(1):51-58. PubMed ID: 37690610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral Vancomycin Prophylaxis as Secondary Prevention Against Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy Population.
    Morrisette T; Van Matre AG; Miller MA; Mueller SW; Bajrovic V; Abidi MZ; Benamu E; Kaiser JN; Barber GR; Chase S; Tobin J; Fish DN; Gutman JA
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):2091-2097. PubMed ID: 31255741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A meta-analysis of metronidazole and vancomycin for the treatment of Clostridium difficile infection, stratified by disease severity.
    Di X; Bai N; Zhang X; Liu B; Ni W; Wang J; Wang K; Liang B; Liu Y; Wang R
    Braz J Infect Dis; 2015; 19(4):339-49. PubMed ID: 26001980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential impact of removing metronidazole from treatment armamentarium of mild acute
    Zilberman-Itskovich S; Youngster I; Lazarovitch T; Bondarenco M; Toledano L; Kachlon Y; Mengesha B; Strul N; Zaidenstein R; Marchaim D
    Future Microbiol; 2019 Nov; 14():1489-1495. PubMed ID: 31913060
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 45.